Neuroscience Biotech Alkermes Sees Narcolepsy R&D as Launchpad for a Range of New Fatigue Therapies

TL;DR


Summary:
- Alkermes, a pharmaceutical company, has developed a new drug called Alixorexton, which is an orexin agonist for the treatment of narcolepsy.
- Orexin is a neurotransmitter that plays a crucial role in regulating sleep and wakefulness, and by targeting orexin receptors, Alixorexton aims to improve the sleep-wake cycle in people with narcolepsy.
- This new drug represents a promising advancement in the field of neuroscience and sleep research, as it offers a potential alternative to current treatments for narcolepsy, which can have significant side effects.

Like summarized versions? Support us on Patreon!